VIIV HEALTHCARE ANNOUNCES HEALTH CANADA APPROVAL FOR APRETUDE (CABOTEGRAVIR TABLETS AND EXTENDED RELEASE INJECTABLE SUSPENSION) FOR PRE-EXPOSURE PROPHYLAXIS (PREP) TO REDUCE THE RISK OF SEXUALLY ACQUIRED HIV